Montanide ISA-51 is licensed for human use in a therapeutical cancer vaccine CimaVax-EGF, which targets stage IIIB/IV non-small-cell lung carcinoma (NSCLC) in Cuba [28]. Here, EGF is linked to non-small cell lung carcinoma.